From: Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients
PatientID | Therapy | Line of therapy | Staging outcome | CTCs before therapy | CTCs during therapy | ||
---|---|---|---|---|---|---|---|
1–4 weeks | 5–8 weeks | 9–12 weeks | |||||
5 | FOLFIRI+Beva | 2 | PD | + | - | - | + |
7 | FUFOX | 2 | PD | + | + | + | + |
8 | FOLFIRI+Beva | 2 | NP | + | + | + | - |
9 | FUFIRI | 2 | PD | + | + | + | + |
15 | FOLFIRI | 1 | PD | - | + | + | + |
36 | FOLFOX-4 | 1 | PD | + | - | + | + |
39 | FUFIRI | 2 | PD | + | - | - | - |
47 | FOLFIRI+Beva | 1 | NP | + | - | - | - |
49 | FOLFOX-4 | 1 | NP | + | - | + | - |
49 | FOLFIRI | 2 | PD | + | + | + | + |
65 | Panitumumab | 2 | NP | - | - | + | - |
65 | Panitumumab | 2 | PD | + | + | + | + |
70 | FOLFOX-4 | 1 | NP | - | - | + | - |
73 | FOLFOX-4 | 1 | PD | + | - | - | + |
74 | FOLFIRI+Beva | 2 | PD | + | + | + | + |
77 | AIO+Beva | 1 | NP | + | + | + | - |
80 | FOLFIRI+Beva | 1 | NP | - | - | - | - |
81 | FUFIRI | 1 | PD | - | + | + | + |
81 | FUFOX | 2 | PD | + | + | + | + |
87 | AIO | 1 | NP | + | - | - | + |
91 | AIO +Beva | 2 | NP | - | - | - | - |
97 | FOLFIRI +Beva | 1 | NP | + | + | + | + |
97 | FOLFIRI +Beva | 1 | PD | + | + | + | - |
99 | FOLFOX-4 | 1 | NP | - | - | - | - |
109 | AIO | 1 | PD | + | + | + | + |
112 | FOLFIR+Beva | 1 | NP | - | + | - | - |
139 | FOLFIR+Beva | 1 | NP | + | + | - | - |
150 | AIO +Beva | 1 | NP | - | - | - | - |
151 | FUFOX | 1 | NP | + | + | - | + |
151 | FUFOX | 1 | PD | + | + | + | + |
171 | FOLFOX-4 | 1 | NP | + | - | - | - |
184 | AIO | 1 | NP | - | - | - | - |
195 | AIO | 1 | PD | + | + | + | + |